FDA Approved Drugs » 2012
Medical Areas: Hematology | Oncology | Family Medicine
View By:Year | Company | Conditions | Therapeutic Areas | Drug Names
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: Onyx Pharmaceuticals
Approval Status: Approved July 2012
Treatment Area: multiple myeloma
Kyprolis (carfilzomib) is a proteasome inhibitor. Carfilzomib had antiproliferative and proapoptotic activities in vitro in solid and hematologic tumor cells. In animals, carfilzomib inhibited proteasome activity in blood and tissue and delayed tumor growth.
Kyprolis is specifically indicated for the treatment of multiple myeloma in patients who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Kyprolis is supplied as a solution for intravenous administration. Kyprolis should be administered intravenously over 2 to 10 minutes, on two consecutive days, each week for three weeks followed by a 12-day rest period. Each 28-day period is considered one treatment cycle. In Cycle 1, Kyprolis should be administered at a dose of 20 mg/m2. If tolerated in Cycle 1, the dose should be escalated to 27 mg/m2 beginning in Cycle 2 and continued at 27 mg/m2 in subsequent cycles. Treatment may be continued until disease progression or until unacceptable toxicity occurs.
FDA ApprovalThe FDA approval of Kyprolis was based on a single-arm, multicenter clinical trial. The trial enrolled 266 subjects with relapsed multiple myeloma who had received at least two prior therapies (including bortezomib and thalidomide and/or lenalidomide). Subjects were enrolled in the trial whose disease had a less than or equal to 25% response to the most recent therapy or had disease progression during or within 60 days of the most recent therapy. Kyprolis was administered intravenously over 2 to 10 minutes on two consecutive days each week for three weeks, followed by a 12-day rest period (28-day treatment cycle), until disease progression, unacceptable toxicity, or for a maximum of 12 cycles. Subjects received 20 mg/m2 at each dose in Cycle 1, and 27 mg/m2 in subsequent cycles. To reduce the incidence and severity of fever, rigors, chills, dyspnea, myalgia, and arthralgia, dexamethasone 4 mg by mouth or by intravenous infusion was administered prior to all Kyprolis doses during the first cycle and prior to all Kyprolis doses during the first dose-escalation (27 mg/m2) cycle. The primary endpoint was the overall response rate (ORR) as determined using International Myeloma Working Group criteria. The ORR (stringent complete response [sCR] + complete response [CR] + very good partial response [VGPR] + partial response [PR]) was 22.9% (N = 266). The median duration of response was 7.8 months.
Adverse events associated with the use of Kyprolis may include, but are not limited to, the following:
Alsina M, Trudel S, Furman RR, Rosen PJ, O'Connor OA, Comenzo RL, Wong AF, Kunkel LA, Molineaux CJ, Goy A A phase 1 single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clinical cancer research : an Official Journal of the American Association for Cancer Research. 2012 Jul 3
Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 2012 Jun 14;119(24):5661-70
For additional information regarding Kyprolis for multiple myeloma, please visit the Kyprolis web page.
Unless otherwise specified, all medical content is compiled by MSF staff and reviewed for accuracy by a member of our Medical Advisory Board.
The MSF strives to present clear and unbiased information. This site is partially funded through a grant from Bayer Healthcare, LLC.
© Copyright 2000-2009 Multiple Sclerosis Foundation - All Rights Reserved